Peripheral Blood S100B Levels in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis

Zheng, Zhen; Zheng, Peng; Zou, Xiaobing

doi:10.1007/s10803-020-04710-1

Cited by 16 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our discussion part we attempt to explain and interpret these issues. In the meta-analysis study by Zheng et al (16), no difference was found between the ASD and control groups in terms of S100B levels in China and Turkey. The authors claimed this might have been related to genetic factors, environmental factors, lifestyle, and economic conditions.…”

Section: Discussionmentioning

confidence: 89%

“…While interpreting all the results, this should be taken into consideration. In the meta-analysis study by Zheng et al (16), it was found that individuals with ASD who had higher peripheral blood S100B levels were detected in cross-sectional studies but not in case-control studies. This situation indicated that the results might have been affected by the study design.…”

Section: Discussionmentioning

confidence: 97%

“…Castellani et al (18) and Bouvier et al (19) found no significant difference between the sexes in children in terms of S100B values. As a meta-analysis has revealed, high levels of heterogeneity were detected in studies conducted for investigation of the association of S100B with ASD (16). While interpreting all the results, this should be taken into consideration.…”

Section: Discussionmentioning

confidence: 99%

“…In the meta-analysis study by Zheng et al (16), it was stated that peripheral blood S100B levels might have potential as a useful biomarker for ASD. In our study there was no difference in serum S100B levels between the study and control groups.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Eraslan

Durukan

Bodur

et al. 2021

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim: Autism spectrum disorder is a neurodevelopmental disorder. The S100 calcium binding protein B (S100B) is among the markers of astrocyte activation as well as brain damage. Herein, it was aimed to evaluate S100B levels to determine whether there is a relation with the severity of autism spectrum disorder and establish possible causes of different results among the studies in the literature from a psychiatric and biochemical perspective. Material and Methods: Twenty-five male children with autism spectrum disorder were included as the study group along with twenty-seven male children as the control group. The childhood autism rating scale and the autism behavior checklist were applied. Serum S100B protein levels were measured by enzyme-linked immunosorbent assay (ELISA). Results:The mean serum S100B level was 1008.61±171.34 pg/mL in the study group and 1060.14±182.83 pg/mL in the control group, and no statistically significant difference was found between the groups (p=0.300). Based on the childhood autism rating scale scores, 60% (n=15) of the children with autism spectrum disorder had severe autism, whereas 40% (n=10) had mild-to-moderate autism. There was no significant difference in terms of the serum S100B levels between the groups of autism spectrum disorder severity (p=0.935) or according to the autistic regression status (p=0.667). Conclusion: For S100B to be accepted as a reliable biomarker for autism spectrum disorder, more studies considering some factors with larger samples should be performed. Moreover, to understand the effect of biochemical methodology on the results, further studies are suggested on this subject.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Eraslan

Durukan

Bodur

et al. 2021

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

“…Для цього вивчили асоціацію негативізації результатів серологічних тестів із нормалізацією раніше підвищених сироваткових концентрацій біомаркерів церебрального пошкодження нейронспецифічної енолази (NSE) і білка S-100 (табл. 1), релевантність яких раніше продемонстрована в спеціально спланованих контрольованих клінічних дослідженнях у дітей із РАС [15,33].…”

Section: рисунок 5 динаміка сироваткових концентрацій антинейрональних автоантитіл у пацієнтів дг (N = 62) і кг (N = 19) протягом курсу іunclassified

Efficacy of rituximab in autism spectrum disorders associated with hereditary folate malabsorption with signs of antineuronal autoimmunity

Maltsev

2021

INJ

View full text Add to dashboard Cite

Background. One of the key advances in psychiatry is an elucidation of the association of hereditary folate malabsorption (HFM) with autistic spectrum disorders (ASD), the evidence for which is based on the results of 5 meta-analyses of randomized controlled trials. It is shown that in such cases the antineuronal autoimmune reaction is an important mechanism of encephalopathy formation. The purpose of the study was to investigate the efficacy of rituximab in children with HFM-associated ASD who showed serological signs of antineuronal autoimmunity to expand the current arsenal of neuroprotective therapy in immunodependent encephalopathy in such cases. Materials and methods. Medical data of 138 children aged 3 to 8 years with HFM and ASD (97 boys and 41 girls) were analyzed. Parents of 62 of 81 patients with signs of antineuronal autoimmunity agreed to rituximab immunotherapy at a dose of 375 mg/m2 of body surface area per month for 3–9 months (study group, SG). Relatives of the other 19 patients with a similar distribution of antineuronal autoantibodies refused treatment (control group, CG). The dynamics of the mental state of children during immunotherapy was assessed by the ABC scale. For statistical analysis, we calculated the parametric Student’s t-test with the confidence probability p and the non-parametric criterion — the number of signs Z by U.V. Urbach, as well as the odds ratio (OR) and 95% confidence interval (95% CI). Results. Rituximab treatment resulted in a progressive decrease in serum antineuronal autoantibodies concentration in patients with ASD associated with HFM, with a more pronounced effect in the production of autoantibodies to neuronal potassium channels compared to autoantibodies to the GADA with complete elimination of the seropositivity after a 9-month course of immunotherapy in 92 % of cases. The phenomenon of rituximab-induced elimination of serum antineuronal autoantibodies is associated with the effect of neuroprotection, which was confirmed by the normalization of previously elevated serum concentrations of laboratory biomarkers of NSE cerebral damage (OR = 17.875; 95% CI = 4.738–67.436 at Ab to GADA and 41.800; 7.257–240.778 at Ab to potassium channels) and S-100 protein (9.750; 2.707–35.113 and 18.333; 3.462–97.083, respectively). In parallel, there was a progressive improvement in all indicators of the mental status of children with ASD on the ABC scale with a latency period of about 2 months (p < 0.05: Z < Z0.05). Conclusions. Immunotherapy with rituximab by eliminating the serological signs of antineuronal autoimmunity realizes the effect of neuroprotection, reducing the severity of all major clinical signs of ASD in children with HFM.

show abstract

Recombinant SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Stimulate Release of Different Pro-Inflammatory Mediators via Activation of Distinct Receptors on Human Microglia Cells

Tsilioni

Theoharides

2023

Mol Neurobiol

View full text Add to dashboard Cite

SARS-CoV-2 infects cells via its spike (S) protein binding to its surface receptor Angiotensin ConvertingEnzyme 2 (ACE2) on target cells and results in acute symptoms involving especially the lungs known as COVID-19. However, increasing evidence indicates that SARS-CoV-2 infection produces neuroin ammation associated with neurological, neuropsychiatric, and cognitive symptoms persists well past the resolution of the infection, known as post-COVID-19 sequalae or Long-COVID. The neuroimmune mechanism(s) involved in Long-COVID have not been adequately characterized. In this study, we show that recombinant SARS-CoV-2 full-length S protein stimulates release of pro-in ammatory IL-1b, CXCL8, IL-6 and MMP-9 from cultured human microglia via TLR4 receptor activation. Instead, recombinant receptor-binding domain (RBD) stimulates release of TNF-α, IL-18 and S100B via ACE2 signaling. These results provide evidence that SARS-CoV-2 spike protein contributes to neuroin ammation through different mechanisms that may be involved in CNS pathologies associated with Long-COVID.

show abstract

Peripheral Blood S100B Levels in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis

Cited by 16 publications

References 36 publications

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Efficacy of rituximab in autism spectrum disorders associated with hereditary folate malabsorption with signs of antineuronal autoimmunity

Recombinant SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Stimulate Release of Different Pro-Inflammatory Mediators via Activation of Distinct Receptors on Human Microglia Cells

Contact Info

Product

Resources

About